NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
3.590
-0.190 (-5.03%)
At close: May 5, 2026, 4:00 PM EDT
3.000
-0.590 (-16.43%)
After-hours: May 5, 2026, 7:12 PM EDT
NewcelX Employees
As of December 31, 2024, NewcelX had 15 total employees, including 11 full-time and 4 part-time employees. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$553,333
Market Cap
16.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 15 | 3 | 25.00% | 11 | 4 |
| Dec 31, 2023 | 12 | -19 | -61.29% | 12 | 0 |
| Dec 31, 2022 | 31 | -1 | -3.13% | 31 | 0 |
| Dec 31, 2020 | 32 | - | - | 28 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| Lipocine | 14 |
| Cocrystal Pharma | 10 |
| Genenta Science | 9 |
| Lexaria Bioscience | 7 |
NCEL News
- 5 days ago - NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - GlobeNewsWire
- 15 days ago - NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - GlobeNewsWire
- 4 weeks ago - NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - GlobeNewsWire
- 2 months ago - NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - PRNewsWire
- 2 months ago - NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy - PRNewsWire
- 3 months ago - NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences - PRNewsWire
- 4 months ago - NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression - PRNewsWire
- 4 months ago - NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board - PRNewsWire